Life Technologies and ProBioGen AG Announce Freedom(TM) Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production

By Life Technologies Corporation, PRNE
Monday, May 16, 2011

New kits provide molecule-to-market bioproduction solutions with unprecedented efficiency and speed

CARLSBAD, California and BERLIN, May 17, 2011 - Life Technologies Corporation ( (NASDAQ: LIFE)
and ProBioGen AG ( today announced the availability
of Gibco(R) Freedom(TM) Cell Line Development Kits
(, a new line of royalty-free products
that integrate cells, reagents, culture media and protocols to bring
simplicity and flexibility, eliminating up to two months in the earliest
stages of new biological drug development. These kits make it easier and
faster to bring new molecules to the market.

Life Technologies' new kits can reduce the time from transfection to
stable cell line production, from six to four months, making unprecedented
use of a single, optimized, animal-free culture medium throughout the entire
development process. This eliminates the need for multiple time consuming and
complicated media adaptation steps.

"Life Technologies' cell line development kits showcase our ability to
integrate proprietary technologies into simple, innovative solutions that
accelerate the pathway from molecule to market," said Mark Stevenson,
President and Chief Operating Officer of Life Technologies. "Our royalty-free
Freedom(TM) kits enable faster early stage development, and allow customers
to focus on what they do best-developing new biologics to treat diseases."

The Freedom(TM) CHO-S(TM) and DG44 Kits provide biopharmaceutical drug
development teams with key components for biotech and pharmaceutical
companies to rapidly and systematically generate Chinese Hamster Ovary (CHO)
cell lines to produce clinical and commercial biologic pharmaceuticals. CHO
cells have been engineered to express recombinant proteins as therapeutics
for a wide range of diseases, including rheumatoid arthritis, anemia,
multiple sclerosis, cancer and non-Hodgkin's lymphoma, and are a critical
part of the $20 billion bioproduction market, which represents nearly 20
percent of biopharmaceutical revenue, according to a report from
ScientiaAdvisors ( .

Life Technologies' Freedom(TM) CHO-S(TM) Kit was developed in
collaboration with ProBioGen AG ( The Freedom(TM)
DG44 Kit was developed by Life Technologies. Both kits include
fully-documented cGMP
cell lines and animal origin-free workflows to take researchers from gene
transfection to the generation of a stable clone. Commercial licensees obtain
a detailed information package with the applicable cell line's lineage and
testing history, to facilitate rapid IND (investigational new drug) filing
with the US Food and Drug Administration prior to performing Phase I clinical

About Life Technologies Bioproduction

Life Technologies is a global leader in bioprocessing products that
support the production of biologics-based therapeutics and vaccines from
molecule to market, with leading brands such as Gibco(R) cell culture
products ( and
cell therapy systems
POROS(R) chromatography
for process-scale bioseparations; and Applied Biosystems(R) SEQ
rapid molecular methods for contaminant detection and identification. Our
customized Gibco(R) media and cell line development services have been used
by leading biotechnology and pharmaceutical companies worldwide to optimize
the productivity of their production platforms. Please follow Life
Technologies' Bioproduction business on Twitter at @molecule2market
( For information about licensing,
please contact

About Life Technologies

Life Technologies Corporation ( (NASDAQ: LIFE)
is a global biotechnology company dedicated to improving the human condition.
Our systems, consumables and services enable researchers to accelerate
scientific and medical advancements that make life even better. Life
Technologies customers do their work across the biological spectrum, working
to advance the fields of discovery and translational research, molecular
medicine, stem cell-based therapies, food safety and animal health, and 21st
century forensics. The company manufactures both molecular diagnostic and
research use only products. Life Technologies' industry-leading brands are
found in nearly every life sciences lab in the world and include innovative
instrument systems under the Applied Biosystems and Ion Torrent names, as
well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion,
Molecular Probes and Taqman products. Life Technologies had sales of $3.6
in 2010, has a workforce of approximately 11,000 people, has a
presence in approximately 160 countries, and possesses one of the largest
intellectual property estates in the life sciences industry, with
approximately 3,900 patents and exclusive licenses. For more information on
how we are making a difference, please visit our website: Follow Life Technologies on Twitter
@LIFECorporation ( and on Facebook

About ProBioGen AG

ProBioGen is a renowned Contract Development and Manufacturing
Organization (CDMO) and Technology Provider, focusing on cell line
engineering, process development (upstream- and downstream) and GMP
manufacturing of biopharmaceuticals. ProBioGen's royalty-free,
fee-for-service- based CHO platform is based on almost 20 years of experience
in mammalian cell culture. Combined with its innovative scientific excellence
and strong intellectual property base, ProBioGen covers the entire drug
development value chain, including regulatory support for IND-filing. All of
ProBioGen's services and technologies are embedded in a total quality
management system to assure compliance with international ISO and GMP
standards (EMA/FDA). ProBioGen was founded in 1994 and is located in Berlin,

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not
limited to, statements as to industry trends and Life Technologies' plans,
objectives, expectations and strategy for its business, contains
forward-looking statements that are subject to risks and uncertainties that
could cause actual results or events to differ materially from those
expressed or implied by such forward-looking statements. Any statements that
are not statements of historical fact are forward-looking statements. When
used, the words "believe," "plan," "intend," "anticipate," "target,"
"estimate," "expect" and the like, and/or future tense or conditional
constructions ("will," "may," "could," "should," etc.), or similar
expressions, identify certain of these forward-looking statements. Important
factors which could cause actual results to differ materially from those in
the forward-looking statements are detailed in filings made by Life
Technologies with the Securities and Exchange Commission. Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


    Life Technologies Contact
    Tim Ingersoll

    ProBioGen Contact
    Gabriele Schneider


will not be displayed